PEXA reported no revenue and a net loss in Q1 2025 as it shifts focus to development and clinical applications. Cash reserves declined, and additional funding is needed, but new studies and patent progress support long-term growth prospects.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.